semaglutide ema GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, Warns Novo Nordisk secures EMA approval

This has solidified the therapeutic and commercial importance of GLP 1 analogues in obesity management, transforming them from niche products into cornerstone therapies for a wide spectrum of cardiometabolic conditions

Heres how to tell the difference and what to do next

Your path to wellness starts with a FREE weight loss consultation at MRC

Just keep in mind that gaining more weight will cause fat to be stored in other areas of your body

Its exhausting to navigate the cycle of losing and regaining the same 15 percent of your body weight, especially when youre caught between the hype of social media and the clinical reality of options like Ozempic and Wegovy

People around the world enjoy its benefits one amazing day at a time